The world’s first ever drug shown to work against Alzheimer’s disease has been developed by scientists.
A “historic” trial of 1,800 participants with early stage disease showed lecanemab reduced decline in memory and thinking skills by 27% over 18 months.
If approved by regulators, it will be the only drug available to treat the underlying disease rather than temporarily manage symptoms.
